
Innovation Conversations: Guiding Nightstar
Robert MacLaren, professor of ophthalmology at Oxford, discusses the gene therapy research behind Nightstar, the spinout company he founded to treat inherited retinal diseases. He explains the science of using viral vectors to deliver corrected genes into the eye, aiming to slow or stop degeneration in conditions that cause blindness, and walks through how laboratory findings moved toward clinical application. The conversation also covers the commercial side of the story, including how Nightstar grew from a university spinout into a company acquired by Biogen for 877 million dollars within five years of founding, one of the largest British biotech exits of the past two decades. MacLaren reflects on what made the translation from bench research to treatment possible, and on the practical and regulatory hurdles facing gene therapy more broadly. The talk sits at the intersection of medical research and research commercialization, told by the scientist who led both sides of it.